Akoya Biosciences Inc (AKYA) - Total Assets
Based on the latest financial reports, Akoya Biosciences Inc (AKYA) holds total assets worth $112.65 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Akoya Biosciences Inc for net asset value and shareholders' equity analysis.
Akoya Biosciences Inc - Total Assets Trend (2019–2024)
This chart illustrates how Akoya Biosciences Inc's total assets have evolved over time, based on quarterly financial data.
Akoya Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Akoya Biosciences Inc's total assets of $112.65 Million consist of 61.4% current assets and 38.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.4% |
| Accounts Receivable | $13.78 Million | 11.0% |
| Inventory | $24.32 Million | 19.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $14.56 Million | 11.7% |
| Goodwill | $18.26 Million | 14.6% |
Asset Composition Trend (2019–2024)
This chart illustrates how Akoya Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Akoya Biosciences Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Akoya Biosciences Inc's current assets represent 61.4% of total assets in 2024, an increase from 45.7% in 2019.
- Cash Position: Cash and equivalents constituted 9.4% of total assets in 2024, down from 13.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, a decrease from 46.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 19.5% of total assets.
Akoya Biosciences Inc Competitors by Total Assets
Key competitors of Akoya Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.14 Billion |
|
Vizionfocus Inc.
TW:4771
|
Taiwan | NT$6.53 Billion |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
Akoya Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.61 | 3.07 | 1.67 |
| Quick Ratio | 0.40 | 2.38 | 1.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-41.87 Million | $68.64 Million | $11.53 Million |
Akoya Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Akoya Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.45 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | -30.7% |
| Total Assets | $125.00 Million |
| Market Capitalization | $64.44 Million USD |
Valuation Analysis
Below Book Valuation: The market values Akoya Biosciences Inc's assets below their book value (0.52x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Akoya Biosciences Inc's assets decreased by 30.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Akoya Biosciences Inc (2019–2024)
The table below shows the annual total assets of Akoya Biosciences Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $125.00 Million | -30.69% |
| 2023-12-31 | $180.37 Million | +2.46% |
| 2022-12-31 | $176.03 Million | -7.79% |
| 2021-12-31 | $190.91 Million | +145.82% |
| 2020-12-31 | $77.66 Million | -13.14% |
| 2019-12-31 | $89.41 Million | -- |
About Akoya Biosciences Inc
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImag… Read more